Which startups have raised the most funding in the healthcare AI market?
Download our beautiful pitch about the healthcare AI market

In our healthcare AI market deck, you will find everything you need to understand the market
The healthcare AI market has become one of the most capital-intensive areas in artificial intelligence, especially in drug discovery, diagnostics, clinical documentation, and healthcare operations.
This list is updated every month, so the ranking stays useful as new rounds, IPOs, acquisitions, and shutdowns change the market.
Below, we rank the top healthcare AI startups by cumulative funding raised, using the funding data available in the dataset.
And if you want to better understand this new industry, you can download our pitch covering the healthcare AI market.
A quick summary table
| Metric | Value |
|---|---|
| Most funded startup | Isomorphic Labs, with $2.7B raised |
| Second most funded startup | Freenome, with $1.4B raised |
| Largest funding round | Isomorphic Labs, $2.1B Series B in May 2026 |
| Median funding | About $167M across the most reliable subset |
| Share of funding captured by the top 10 | About 53% of reliable healthcare AI funding |
| Median time since last round | About 24 months |
| Startups that raised funding in the last 12 months | 24 startups |
| Healthcare AI startups above $1B raised | 6 startups in the full ranking |
| Drug discovery share of reliable funding | About 57% |
| Clinical AI documentation funding leaders | Abridge, Hippocratic AI, Ambience Healthcare, and Nabla |

This chart, featured in our healthcare AI market deck, shows annual VC investment in healthcare AI startups
Top startups in the healthcare AI market ranked by total funding raised
Here is an updated table that ranks the top startups in the healthcare AI market based on the total amount of funding they have raised to date.
The table also includes the total number of funding rounds, the date and size of the latest round, the financing type (e.g. Series A, equity financing), key investors, the startup’s current status (active, IPO, acquired, or shut down), and a confidence score based on the data collected (we excluded startups with very low data confidence, to make sure everything is reliable).
If you're interested in knowing how much these startups are worth, you can check our list of the top startups in the healthcare AI market ranked by valuation.
| # | Startup | What They Do | Total Raised ($) | Total Rounds | Last Round Date | Last Round Amount ($) | Last Round Type | Key Investors | Current Stage | Confidence |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Isomorphic Labs | AI drug discovery engine | $2.7B | 2 | May 2026 | $2.1B | Series B | Thrive Capital, Alphabet, GV | Active | Full |
| 2 | Freenome | Early cancer blood testing | $1.4B | 8 | February 2024 | $254M | Series E / new funding | Roche, a16z, ARK Venture Fund | Active | Full |
| 3 | Tempus | AI precision medicine data | $1.2B | 9 | June 2024 | $411M | IPO | Public markets, Google, Baillie Gifford | IPO | Partial |
| 4 | HeartFlow | AI coronary artery diagnostics | $1.1B | 10 | August 2025 | $364M | IPO | Public markets, Bain Capital Life Sciences, USVP | IPO | Partial |
| 5 | Recursion Pharmaceuticals | AI-driven drug discovery platform | $1.1B | 7 | July 2023 | $50M | PIPE | NVIDIA | IPO | Full |
| 6 | Xaira Therapeutics | AI drug discovery biotech | $1.0B | 1 | April 2024 | $1.0B | Series A | ARCH Venture Partners, Foresite Capital, Sequoia Capital | Active | Full |
| 7 | Relay Therapeutics | Protein-motion drug discovery | $920M | 4 | July 2020 | $400M | IPO | SoftBank Vision Fund, BVF Partners, Third Rock Ventures | IPO | Full |
| 8 | XtalPi | AI drug discovery robotics | $911M | 6 | June 2024 | $127M | IPO | OrbiMed, HOPU, SoftBank Vision Fund | IPO | Strong |
| 9 | Olive AI | Healthcare admin automation AI | $856M | 9 | July 2021 | $400M | Series H / Growth | Vista Equity Partners, Base10, Tiger Global | Shutdown | Partial |
| 10 | Exscientia | AI drug discovery | $839M | 6 | October 2021 | $160M | Concurrent private placement | SoftBank, Gates Foundation | Acquired | Strong |
| 11 | Insilico Medicine | Generative AI drug discovery | $811M | 7 | December 2025 | $293M | IPO | Value Partners, Warburg Pincus, Qiming | IPO | Strong |
| 12 | Abridge | AI clinical documentation | $758M | 7 | June 2025 | $300M | Series E | Andreessen Horowitz, Khosla Ventures, Lightspeed Venture Partners | Active | Strong |
| 13 | OpenEvidence | Medical evidence AI search | $735M | 11 | January 2026 | $250M | Series D | Thrive Capital, DST Global, GV | Active | Partial |
| 14 | BenevolentAI | AI drug discovery platform | $734M | 4 | April 2022 | $442M | SPAC listing proceeds | Odyssey Acquisition, Temasek, AstraZeneca | Acquired | Partial |
| 15 | Generate:Biomedicines | Generative protein therapeutics discovery | $693M | 3 | September 2023 | $273M | Series C | Amgen, NVentures, MAPS Capital | Active | Full |
| 16 | AbCellera | AI antibody discovery platform | $671M | 3 | December 2020 | $556M | IPO | OrbiMed, DCVC Bio, Viking Global Investors | IPO | Full |
| 17 | insitro | ML-powered drug discovery | $643M | 3 | March 2021 | $400M | Series C | CPP Investments, SoftBank Vision Fund 2, a16z | Active | Full |
| 18 | Formation Bio | AI-native drug development | $608M | 3 | June 2024 | $372M | Series D | a16z, Sanofi, Sequoia | Active | Partial |
| 19 | METiS Therapeutics | AI drug delivery platform | $576M | 6 | May 2026 | $269M | IPO | BlackRock, PICC PE, China Life | IPO | Partial |
| 20 | Commure | Healthcare operations AI platform | $570M | 7 | May 2026 | $70M | Equity financing | General Catalyst, Sequoia Capital, Morgan Stanley | Active | Partial |
| 21 | Innovaccer | Healthcare intelligence cloud | $547M | 7 | January 2025 | $179M | Series F | B Capital Group, Kaiser Permanente, M12 | Active | Partial |
| 22 | Komodo Health | Healthcare data analytics platform | $514M | 4 | November 2022 | $200M | Structured equity | Coatue, Dragoneer | Active | Strong |
| 23 | Medable | Decentralized clinical trial platform | $507M | 6 | October 2021 | $304M | Series D | Blackstone Growth, GSR Ventures, Tiger Global | Active | Strong |
| 24 | Saama | AI clinical data analytics | $505M | 3 | October 2021 | $430M | Strategic Growth Equity | Carlyle, Merck GHI, Pfizer Ventures | Acquired | Partial |
| 25 | SOPHiA GENETICS | Data-driven medicine analytics | $503M | 7 | July 2021 | $254M | IPO / Private Placement | aMoon, Generation Investment, Balderton Capital | IPO | Partial |
| 26 | Pathos AI | AI oncology drug development | $467M | 3 | May 2025 | $365M | Series D | NEA, Revolution Growth, Lightbank | Active | Partial |
| 27 | Biofourmis | AI remote patient monitoring | $461M | 6 | August 2022 | $20M | Series D extension | Intel Capital, General Atlantic, CVS Health | Acquired | Strong |
| 28 | Exo | AI handheld ultrasound platform | $420M | 5 | May 2025 | $100M | Series D / venture | Samsung Ventures, RA Capital Management, BlackRock | Active | Partial |
| 29 | Hippocratic AI | Healthcare LLM agents | $404M | 4 | November 2025 | $126M | Series C | Avenir Growth | Active | Strong |
| 30 | Aidoc | Clinical imaging AI platform | $400M | 5 | April 2026 | $150M | Series E | Goldman Sachs Alternatives, General Catalyst, SoftBank Investment Advisors | Active | Strong |
| 31 | Valo Health | AI-enabled drug development | $400M | 3 | March 2021 | $110M | Series B final close | Koch Disruptive Technologies, Flagship Pioneering, PSP Investments | Active | Partial |
| 32 | Cleerly | AI cardiac imaging | $383M | 4 | December 2024 | $106M | Series C extension | Insight Partners, Battery Ventures | Active | Partial |
| 33 | Huma | AI digital health platform | $355M | 13 | April 2025 | $17M | Late-stage / undisclosed | Nomura, Lumos Capital Group, HAT | Active | Partial |
| 34 | Ambience Healthcare | Ambient clinical documentation AI | $343M | 3 | July 2025 | $243M | Series C | Oak HC/FT, Andreessen Horowitz, OpenAI Startup Fund | Active | Strong |
| 35 | Iambic Therapeutics | AI-designed therapeutics platform | $334M | 5 | April 2026 | $28M | Series C-II | Abingworth, Ascenta, Illumina Ventures | Active | Partial |
| 36 | Clarify Health Solutions | Healthcare analytics value-based payments | $332M | 4 | April 2022 | $150M | Series D | SoftBank Vision Fund 2, BlackRock, Insight Partners | Active | Partial |
| 37 | Owkin | Federated AI drug discovery | $304M | 5 | June 2022 | $86M | Series B extension | Sanofi, Bristol Myers Squibb, Mubadala | Active | Strong |
| 38 | Lunit | AI cancer imaging diagnostics | $301M | 7 | April 2026 | $140M | Rights offering | Atinum Investment | IPO | Strong |
| 39 | Immunai | AI immune-system mapping | $295M | 3 | October 2021 | $215M | Series B | Koch Disruptive Technologies, Talos VC, 8VC | Active | Full |
| 40 | Genesis Therapeutics | AI small-molecule drug discovery | $280M | 4 | August 2023 | $200M | Series B | a16z, BlackRock, Fidelity | Active | Strong |
| 41 | Iterative Health | AI gastroenterology clinical research | $262M | 4 | April 2026 | $77M | Series C | Intrepid Growth Partners, GV, EDBI | Active | Strong |
| 42 | Viz.ai | AI care coordination imaging | $250M | 5 | April 2022 | $100M | Series D | Tiger Global, Insight Partners, Scale Venture Partners | Active | Strong |
| 43 | Paige | AI digital pathology diagnostics | $241M | 8 | January 2023 | $20M | Strategic / later equity | Microsoft | Acquired | Strong |
| 44 | PathAI | AI pathology analysis | $240M | 4 | May 2021 | $165M | Series C | D1 Capital Partners, Kaiser Permanente, Tiger Global | Acquired | Strong |
| 45 | Chai Discovery | AI molecular design platform | $230M | 3 | December 2025 | $130M | Series B | General Catalyst, Oak HC/FT, OpenAI | Active | Full |
| 46 | Atomwise | AI small-molecule screening | $219M | 4 | February 2025 | $45M | Series C | Leaps by Bayer, B Capital, DCVC | Active | Strong |
| 47 | Qventus | AI care operations automation | $200M | 6 | January 2025 | $105M | Series D | KKR, Bessemer Venture Partners, Northwestern Medicine | Active | Strong |
| 48 | Cohere Health | AI prior authorization platform | $196M | 5 | May 2025 | $90M | Series C | Temasek, Deerfield, Define Ventures | Active | Strong |
| 49 | BenchSci | AI preclinical R&D platform | $170M | 8 | May 2023 | $70M | Series D | Generation Investment Management, Inovia, TCV | Active | Partial |
| 50 | Suki | AI clinical assistant | $168M | 6 | January 2025 | Undisclosed | Venture / undisclosed | Hedosophia, Venrock, March Capital | Active | Strong |
| 51 | Eko Health | AI heart-lung diagnostics | $165M | 6 | June 2024 | $41M | Series D | ARTIS Ventures, Highland Capital Partners, NTTVC | Active | Strong |
| 52 | Profluent | AI protein design | $150M | 3 | November 2025 | $106M | Series B | Altimeter Capital, Bezos Expeditions, Spark Capital | Active | Full |
| 53 | Rad AI | Generative radiology workflow automation | $147M | 5 | May 2025 | $8M | Series C extension | Advocate Health, Memorial Hermann, Corewell Health | Active | Strong |
| 54 | Unlearn | Clinical trial digital twins | $135M | 7 | February 2024 | $50M | Series C | Altimeter Capital, Radical Ventures, Mubadala Capital | Active | Strong |
| 55 | Verge Genomics | AI neurodegenerative drug discovery | $134M | 4 | December 2021 | $98M | Series B | BlackRock, Eli Lilly, Merck GHI | Active | Strong |
| 56 | Proscia | AI digital pathology platform | $128M | 6 | March 2025 | $50M | Series C / Growth | Insight Partners, AI Capital Partners, Triangle Peak Partners | Active | Full |
| 57 | Qure.ai | AI radiology diagnostics | $121M | 3 | September 2024 | $65M | Series D | Lightspeed, 360 ONE Asset, Merck GHI | Active | Strong |
| 58 | Nabla | Ambient clinical AI assistant | $120M | 3 | June 2025 | $70M | Series C | HV Capital, Highland Europe, DST Global | Active | Strong |
| 59 | Augmedix | Ambient medical documentation | $118M | 8 | November 2023 | $29M | Public Offering | HCA Healthcare, Redmile Group, DCM Ventures | Acquired | Partial |
| 60 | Notable | Healthcare workflow automation | $117M | 3 | November 2021 | $100M | Series B | ICONIQ Growth, Greylock, F-Prime Capital | Active | Full |
| 61 | Healx | AI rare-disease drug discovery | $115M | 5 | July 2025 | $2M | Series C-II | SCI Ventures, Atomico, R42 Group | Active | Partial |
| 62 | AliveCor | AI personal ECG devices | $114M | 6 | August 2022 | Undisclosed | Series F | GE Healthcare, Khosla Ventures, Qualcomm Ventures | Active | Partial |
| 63 | CodaMetrix | Autonomous medical coding | $111M | 4 | May 2025 | $12M | Series B-II | Transformation Capital, SignalFire, Frist Cressey Ventures | Active | Strong |
| 64 | Ibex Medical Analytics | AI cancer pathology diagnostics | $104M | 3 | September 2023 | $55M | Series C | 83North, Sienna Venture Capital, Octopus Ventures | Active | Strong |
| 65 | Ultromics | AI echocardiography heart diagnostics | $103M | 4 | July 2025 | $55M | Series C | L&G, Allegis Capital, Lightrock | Active | Partial |
| 66 | Aqemia | Physics AI drug discovery | $103M | 4 | December 2024 | $38M | Series A / growth extension | Cathay Innovation, Eurazeo, Bpifrance | Active | Strong |
| 67 | RapidAI | AI stroke imaging workflow | $100M | 2 | July 2023 | $75M | Series C | Vista Credit Partners | Active | Full |
| 68 | CytoReason | Computational disease models | $100M | 2 | July 2024 | $80M | Series C / Strategic Equity | OurCrowd, NVIDIA, Pfizer | Active | Partial |
| 69 | Lantern Pharma | AI precision oncology therapeutics | $98M | 6 | May 2026 | $4M | Registered Direct Offering | Bios Partners, GPG Ventures, institutional investor | IPO | Partial |
| 70 | Nym | Explainable autonomous medical coding | $95M | 4 | October 2024 | $47M | Growth Equity | PSG, GV, Addition | Active | Full |
| 71 | Causaly | Biomedical knowledge AI platform | $93M | 5 | July 2023 | $60M | Series B | ICONIQ Growth, Index Ventures, Marathon | Active | Strong |
| 72 | Corti | Healthcare AI co-pilot | $92M | 3 | September 2023 | $60M | Series B | Prosus Ventures, Atomico, Eurazeo | Active | Strong |
| 73 | AKASA | AI revenue-cycle automation | $85M | 3 | March 2021 | $60M | Series B | BOND, Andreessen Horowitz, Costanoa Ventures | Active | Full |
| 74 | TandemAI | AI wet-lab drug discovery | $82M | 3 | November 2025 | $22M | Series A Extension | V-Capital, KHK Fund, Qiming | Active | Full |
| 75 | Regard | AI clinical insights platform | $81M | 3 | July 2024 | $61M | Series B | Oak HC/FT, Cedars-Sinai Health Ventures, TenOneTen Ventures | Active | Partial |
| 76 | Memora Health | Digital care navigation platform | $81M | 3 | April 2023 | $30M | Strategic investment | General Catalyst, Northwell Holdings, NorthShore–Edward-Elmhurst | Acquired | Partial |
| 77 | Lindus Health | AI-enabled clinical trials | $78M | 3 | January 2025 | $55M | Series B | Balderton Capital, Creandum, Seedcamp | Active | Full |
| 78 | SmarterDx | Clinical revenue integrity AI | $71M | 3 | April 2025 | Undisclosed | Series B / Strategic | Transformation Capital, Bessemer, Flare Capital | Active | Partial |
| 79 | Arterys | Cloud AI medical imaging | $70M | 4 | May 2020 | $28M | Series C | Benslie Investment Group, Temasek, Varian | Acquired | Strong |
| 80 | Janus AI | Revenue cycle automation AI | $63M | 3 | September 2024 | $10M | Series B-II / extension | CU Healthcare Innovation Fund, Enhanced Healthcare Partners, Caduceus | Active | Partial |
| 81 | Turbine | Virtual cell simulations | $62M | 4 | February 2026 | $25M | Series B | Interactive Venture Partners, MSD GHI, Accel | Active | Partial |
| 82 | DeepScribe | Ambient AI medical scribe | $60M | 3 | January 2022 | $30M | Series A | Index Ventures, Bee Partners, Stage 2 Capital | Active | Partial |
| 83 | Tandem Health | AI clinician documentation copilot | $60M | 2 | June 2025 | $50M | Series A | Kinnevik, Northzone, Amino Collective | Active | Full |
| 84 | Caption Health | AI-guided ultrasound scanning | $59M | 2 | July 2020 | $53M | Series B | DCVC, Khosla Ventures, Edwards Lifesciences | Acquired | Partial |
| 85 | Aignostics | AI pathology precision medicine | $54M | 3 | October 2024 | $34M | Series B | ATHOS, Mayo Clinic, HTGF | Active | Full |
| 86 | Manas AI | AI cancer drug discovery | $51M | 2 | September 2025 | $26M | Seed Extension | The General Partnership, Mosaic Ventures, Blitzscaling Ventures | Active | Full |
| 87 | Zebra Medical Vision | AI radiology image analysis | $50M | 3 | June 2018 | $30M | Series C | aMoon Ventures, Aurum, Johnson & Johnson Innovation | Acquired | Full |
| 88 | Deep 6 AI | Clinical trial patient matching | $50M | 5 | April 2022 | $27M | Series C / Undisclosed | Point72 Ventures, GSR Ventures, Techstars | Active | Partial |
| 89 | ClosedLoop | Healthcare predictive AI platform | $45M | 2 | August 2021 | $34M | Series B | Telstra Ventures, Breyer Capital, Greycroft | Active | Strong |
| 90 | Ezra | AI full-body MRI screening | $43M | 3 | February 2024 | $21M | Series B | Healthier Capital, FirstMark Capital, Amir Dan Rubin | Acquired | Strong |
| 91 | Quris-AI | AI clinical-prediction platform | $37M | 3 | December 2022 | $9M | Seed Extension | SoftBank Vision Fund 2, Welltech Ventures, iAngels | Active | Strong |
| 92 | SigTuple | AI diagnostic microscopy automation | $33M | 5 | August 2024 | $4M | Series C extension | SIDBI Venture Capital, Accel, Endiya Partners | Active | Strong |
| 93 | Empatica | AI medical wearables biomarkers | $33M | 3 | August 2022 | $26M | Series B | Sanofi Ventures, RA Capital Management, Black Opal Ventures | Active | Strong |
| 94 | Frontera Health | AI-enabled autism care | $32M | 1 | February 2025 | $32M | Seed | Lux Capital, Lightspeed Venture Partners, Menlo Ventures | Active | Strong |
| 95 | Sift Healthcare | AI healthcare payments intelligence | $30M | 3 | May 2024 | $20M | Series B | B Capital, Allos Ventures, First Trust Capital Partners | Active | Partial |
| 96 | QuantHealth | AI clinical trial simulation | $30M | 4 | October 2025 | $10M | Strategic investment | Sanofi Ventures, Accenture Ventures, Pitango HealthTech | Active | Partial |
| 97 | Kheiron Medical Technologies | AI breast cancer screening | $22M | 2 | September 2019 | $22M | Series A | Atomico, Connect Ventures, Greycroft | Acquired | Partial |
| 98 | Iktos | Generative AI drug design | $16M | 1 | March 2023 | $16M | Series A | M Ventures, Debiopharm, Omnes Capital | Active | Full |
| 99 | OneThree Biotech | AI drug discovery platform | $3M | 1 | March 2020 | $3M | Seed | Primary Venture Partners, Meridian Street Capital, What If Ventures | Active | Partial |

This market map, featured in our healthcare AI market deck, highlights top companies and startups in the healthcare AI market
Key funding trends in the healthcare AI market
Insights
- Healthcare AI funding is highly concentrated, since the top 10 companies capture about 53% of reliable funding, even though the ranking includes many more startups.
- Drug discovery is the deepest capital pool in healthcare AI, with 20 companies raising about $11.9B, or roughly 57% of reliable funding in the dataset.
- Healthcare AI drug discovery startups raise much larger rounds than diagnostics companies, with an average near $596M versus roughly $160M for diagnostics, imaging, and pathology players.
- Clinical documentation AI is now a serious late-stage category, as Abridge, Hippocratic AI, Ambience Healthcare, and Nabla have become some of the best funded software-first companies in the market.
- Isomorphic Labs and Xaira Therapeutics show that a healthcare AI startup can reach billion-dollar funding scale with very few rounds when investors believe the platform can reshape drug discovery.
- Recent funding remains active, with companies that raised in 2025 or later collecting about $8.0B, helped by large rounds in drug discovery, clinical documentation, and healthcare operations.
- IPO stories cluster around capital-heavy healthcare AI categories, especially drug discovery, antibody discovery, and imaging diagnostics, where long timelines often require access to public markets.
- Strategic investors appear again and again across the healthcare AI market, which suggests that distribution, clinical access, data access, and pharma partnerships matter as much as capital.

As this chart shows, and as featured in our healthcare AI market deck, search interest in healthcare AI has grown rapidly
A few word about our methodology
As you can see, we built a database that ranks startups in the healthcare AI market based on total cumulative fundraising. To create this ranking, we reviewed many sources and cross-checked information across multiple places.
Whenever possible, we prioritized official company communications, since official announcements are usually the most reliable source for funding amounts, round dates, and investor names. When those were not available, we relied on reputable industry sources such as TechCrunch, Crunchbase, Financial Times or Forbes (to name a few).
We excluded random blogs, unverified websites, and any sources that could not be validated.
When funding rounds were announced in other currencies such as euros, Swiss francs, Singapore dollars, Australian dollars, or rupees, we converted them into approximate USD equivalents for consistency.
Sometimes different sources report slightly different numbers, or the exact round size is not fully disclosed. In those cases, we flag the uncertainty and assign a confidence label to each healthcare AI startup, visible in the last column.
Here is what they mean.
Full confidence: The company’s equity fundraising history can be reconstructed completely from public sources. The rounds, dates, amounts, and key investors are clearly identified, with no meaningful gaps.
Strong confidence: The fundraising history is largely complete and reliable. There may be a small missing detail, such as incomplete investor information or a minor round with limited data, but the overall record is clear.
Partial confidence: The main fundraising rounds can be identified, but the record is incomplete or somewhat mixed. Some rounds may be missing or certain funding events may be difficult to separate clearly.
Low confidence: Public information is too limited, inconsistent, or ambiguous to reliably reconstruct the company’s equity fundraising history.
When the confidence level is too low, we take a conservative approach and exclude the company from the ranking. We don’t want to include data that cannot be reliably verified.
This reflects how we conduct all our research, including the work behind our report covering the healthcare AI market.
In a world where LLMs hallucinate and unreliable information is everywhere, our goal is simple: provide data you can trust.
If you want the full detail on a specific calculation, feel free to contact us and we will gladly explain.
Finally, know that we update the dataset once per month, so come back here if you need fresh information.

This chart, featured in our healthcare AI market deck, looks at Tempus AI’s strategy in healthcare AI
Related blog posts
- What is the latest news in healthcare AI?
- What is the latest funding news in healthcare AI?
- What is the latest update in healthcare AI?
- How funding activity has changed in healthcare AI
- What are the latest fundraising trends in healthcare AI?
- What is the real size of the healthcare AI market?
- A complete list of business models in the healthcare AI market
Who is the author of this content?
NEW MARKET PITCH TEAM
We track new markets so founders and investors can move fasterWe build living “market pitch” documents for emerging markets: from AI to synthetic biology and new proteins. Instead of digging through outdated PDFs, random blog posts, and hallucinated LLM answers, our clients get a clean, visual, always-updated view of what’s really happening. We map the key players, deals, regulations, metrics and signals that matter so you can decide faster whether a market is worth your time. Want to know more? Check out our about page. You can also follow us on Instagram or on Facebook.
How we created this content 🔎📝
At New Market Pitch, we kept seeing the same problem: when you look at a new market, the data is either missing, paywalled, or buried in 300-page reports that feel like they were written in the 80s. On the other side, LLMs and random blog posts give you confident answers with no sources, and sometimes they just make things up. That’s not good enough when you’re about to invest real money or launch a company.
So we decided to fix the experience. For each market we cover, we build a structured database and update it on a regular basis. We track funding rounds, fund memos, M&A moves, partnerships, new products, policy changes, and the real activity of startups and incumbents. Then we turn all of that into a clear “market pitch” that shows where the opportunities are and how people actually win in that space.
Every key data point is checked, sourced, and put back into context by our team. That’s how we can give you both speed and reliability: fast coverage of new markets, without the usual guesswork.